ABBV and LLY Related Headlines
Go Back- Trump to unveil more discounted prescription drug options - CNBC
- Health officials explore restrictions on certain SSRI antidepressants - Reuters
- Bernstein on US Pharma and Biotech: Who might buy whom?
- Barclays launches U.S. biopharma coverage with four preferred picks
- Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
- Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
- Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks
- This U.S. biotech stock is Bernstein's Top Pick for 2026
- Trump to announce prescription drug price agreements
- Bernstein on IRA pricing: $245 really is the floor
- Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
- Abbvie (ABBV) PT Raised to $284 at Piper Sandler
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
- Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
- Buy this U.S. large-cap biopharma stock: JPMorgan
- Prime Medicine stock soars amid gene editing sector momentum
ABBV and LLY Related Press Releases
Go Back- Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
- Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
- Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
